Full Course Description

Pharmacology of Infectious Diseases & Immunizations

Program Information



  • Drug classes
  • Pharmacokinetic Properties
    • Concentration-dependent killing
    • Time-dependent killing
    • Post-antibiotic effect
  • Common interactions with other drugs

Antibacterial Allergies – Sulfa and Penicillin

  • Define true allergy
  • Sulfonamide antibiotics vs non-antibiotics
  • Penicillin – Cephalosporin cross-sensitivity


  • Differentiation
  • Normal flora
  • Common pathogens

Antibacterial Resistance–Contributing Factors

  • Trends
  • Mechanisms of resistance
  • Contributing factors

Methicillin-Resistant Staphylococcus Aureus - Community versus Hospital Acquired

  • Differentiating between CA- and HA-MRSA
  • Current clinical practice guidelines
  • Pharmacologic management

Enterobacteriaceae Resistance

  • Extended Spectrum Beta-Lactamase (ESBL)
    • What are ESBLs
    • Pharmacologic management
  • Carbapenem-Resistant Enterobacteriaceae (CRE)
    • What are CREs
    • Pharmacologic management

Urinary Tract Infections

  • Bacterial Etiology, Signs and Symptoms and Diagnosis
  • Cystitis and pyelonephritis
  • Complicated and uncomplicated
  • UTIs in pregnancy
  • Treatment (IDSA Guideline Treatment Algorithm)
    • Acute
    • Recurrent and relapse

Clostridium Difficile Infection

  • Risk factors
  • Pharmacology management
  • Fecal Transplantation
  • Probiotics literature review

Community–Acquired Pneumonia

  • Bacterial etiology
  • Diagnosis
  • Typical vs. atypical
  • Treatment (IDSA/ATS Guidelines) and monitoring
    • Outpatient vs. inpatient
    • Empiric treatment

Healthcare–Associated Pneumonia

  • Bacterial etiology
  • Treatment (IDSA/ATS Guidelines)
  • Treatment Controversy

Upper Respiratory Tract Infections

  • Sinusitis and pharyngitis
    • Etiology (Viral vs. Bacterial)
    • Treatment
  • Bronchitis and Pertussis
    • Etiology (Viral vs. Bacterial)
    • Treatment

Skin and Soft Tissue Infections

  • Cellulitis
  • Diabetic foot infections
  • Bacterial etiology
    • Signs & symptoms
    • Treatment (IDSA Guidelines)
  • Osteomyelitis
    • Acute vs. Chronic
    • Oral considerations

Strategies to Improve Patient Adherence

  • IMS Model (Information-Motivation-Strategy)
  • Major predictors of poor adherence to medication

Antibacterial Resistance–Prevention Strategies

  • Mechanisms for drug resistance
  • 12 steps to prevent antimicrobial resistance (CDC)
  • Antibiotic stewardship

Emerging and Reemerging Viral Infections

  • Animals as sources
  • Drivers and ecological factors
  • Modes of transmission
  • Pharmacology management


  • Clinical features
  • Diagnosis
  • Pharmacology management

Immunizations (Adult)

  • Types of Vaccines
  • General recommendations
  • Contraindications & precautions


  1. Analyze the major classes of antibiotics and their pharmacokinetic characteristics.
  2. Apply current evidenced-based approaches to select appropriate treatment regimens for common infections encountered in clinical practice.
  3. Point out the different types of bacterial etiology and mechanisms of resistance.
  4. Evaluate empiric dosing of antimicrobials.
  5. Communicate important interactions between antimicrobials and other drugs.
  6. Plan goals of therapy and parameters for monitoring therapeutic response to antimicrobials.
  7. Recommend specific antimicrobial therapeutic drug monitoring to maximize efficacy and minimize toxicities (e.g., vancomycin and aminoglycosides).
  8. Develop preventative strategies to limit antimicrobial resistance.
  9. Design patient and caregiver education on the proper use of antimicrobials.
  10. Breakdown local and global ecological factors affecting promotion of viral infection emergence.
  11. Plan for vaccines that are currently recommended for routine administration.

Target Audience

Nurses, Midwives, Pharmacists, Physician Assistants, and other Healthcare Professionals

Copyright : 03/15/2016

Cardiac Medications: Management of Complex Cardiovascular Disorders

Program Information

Target Audience

Nurses, Pharmacists and Physician Assistants


Hemodynamics and Shock

  • Physiological determinants of myocardial performance
  • Vasodilators
    • Vasopressors
    • Inotropes
    • Shock: Dopamine versus Norepinephrine
    • Nuances of decompensated heart failure

Risk Factor Optimization

  • Statin therapy in primary and secondary prevention
  • Other Antilipid agents: when to use what?
  • Outcome trials for lipid lowering agents
    • AIM High
    • Thrive
  • Drug choices in hypertension
  • Resistant hypertension

Atrial Fibrillation

  • Antiarrhythmic pharmacology for rate control
  • Antiarrhythmic pharmacology for rhythm control
  • Clinical implications of potassium channel blockers
  • Special considerations for Dronedarone and Amiodarone
  • Anticoagulant medication options
    • Fibrinolytics
    • Anticoagulants
    • Antiplatelets

Therapeutic Advances for Acute Coronary Syndrome

  • Prasugrel
  • Ticagrelor
  • Epleranone post-STEMI
  • Non-Steroidals
  • ASA and CABG
  • Contrast nephropathy

Heart Failure

  • Optimal loop diuretic / dose and route of administration
  • Nesiritide
  • OPTIME Trial
  • Serelaxin
  • RAAS drugs
  • Evidence-based beta blockers
  • Drugs not to give for systolic dysfunction

Pulling it All Together: A Patient-Centered Approach to Pharmacology and Prescribing


  1. Justify the physiological basis for cardiovascular drugs used to support hemodynamics and optimize cardiac output.
  2. Select options in the treatment of dyslipidemia and hypertension by contrasting the differences in lipid lowering agents and comparing the similarities in antihypertensive agents.
  3. Communicate key evidence that guides decision-making regarding pharmacological choices in patients with atrial fibrillation.
  4. Assess the pharmacology in the patient with acute coronary syndrome with short-term and long-term treatment goals.
  5. Determine the role of pharmacological agents in interrupting abnormal neurohormonal responses in patients with heart failure.
  6. Evaluate patient partnering as a method of optimizing medication effectiveness.

Copyright : 03/11/2016